12 Amendments of Anja HAZEKAMP related to 2021/2013(INI)
Amendment 95 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas intensive animal husbandry, with large numbers of animals crowded together, leads to excessive use of veterinary pharmaceuticals, including antibiotics, as well as outbreaks of zoonotic diseases;
Amendment 333 #
Motion for a resolution
Paragraph 9
Paragraph 9
Amendment 431 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12 a. Notes that there is significant public demand for the adoption and implementation of a new legislative framework to eliminate animal testing; calls on the Commission to stimulate research for the development of alternative non-animal testing methods applicable to pharmaceuticals; notes that the EU should intensify its international cooperation on alternative testing methods under EPAA, ICRR and ICATM; stresses that the objective of these efforts must be a complete phase-out of animal testing in the EU;
Amendment 517 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Highlights the fact that gene and cell therapies, personalised medicine, nanotechnology, next-generation vaccines, e-health and the ‘Million plus genomes’ initiative can bring enormous benefits in relation tofor the prevention, diagnosis, treatment and post-treatment of all diseases are potentially hazardous and should therefore be used only with great care and in accordance with the precautionary principle; urges the Commission to develop appropriate regulatory frameworks, to guide new business models, and to run information campaigns to raise awareness and encourage the use of these innovations;
Amendment 545 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Urges the Commission, based on the experience with the authorisation of COVID-19 vaccines, to work with the EMA to consider extending the application of rolling reviews to other emergency medicines; further cCalls on the Commission to work with the EMA to develop the use of electronic product information for all medicines in the EU;
Amendment 657 #
Motion for a resolution
Paragraph 22
Paragraph 22
22. Stresses the need for the pharmaceutical industry to be environmentally friendly and climate- neutral throughout the life cycles of medicinal products; calls on the Commission to strengthen inspection and auditing throughout the production chain; urges the Commission to ensure quality environmental sustainability standards for active pharmaceutical ingredients imported from non-EU countries; welcomes the intention to revise the pharmaceuticals legislation; calls on the Commission to address the problem of domestic pharmaceutical waste, with measures to reduce packaging and the size of containers to ensure they are no larger than necessary, and to bring medical prescriptions into line with real therapeutic needs; commends the Commission's intention to consider advertising, marketing and prescription of pharmaceuticals having negative environmental impact; calls on the Commission to include an ERA that assesses the impact of pharmaceutical substances, their degradation products and metabolites on the quality of surface and ground water bodies, including drinking water resources, in the risk- benefit analysis; urges the Commission to speed up the catch-up procedure for ERA of pharmaceuticals authorised before 2006;
Amendment 666 #
Motion for a resolution
Paragraph 22 – point c (new)
Paragraph 22 – point c (new)
(c) Highlights the importance of faster, more ambitious and targeted action to eliminate the environmental risks posed by pharmaceuticals, including and based on research providing a better understanding of the impact of pharmaceuticals on human health, animal health and the environment;
Amendment 667 #
Motion for a resolution
Paragraph 22 – point a (new)
Paragraph 22 – point a (new)
(a) Recalls that information such as the impact of pharmaceuticals on water, environmental behaviour, degradability and potential cocktail effects, plays a key role in risk management and that this type of information should be transparant and made available to all relevant stakeholders; calls on the Commission and the relevant authorities to set up a secure, centralised database enabling all stakeholders concerned to have access to the results of environmental risk assessment;
Amendment 682 #
Motion for a resolution
Paragraph 22 – point b (new)
Paragraph 22 – point b (new)
(b) Calls on the Member States and the Commission to support research, development and innovation in the field of pharmaceuticals that are equally effective for patients as well as harmless to animal health and the environment, given that green pharmaceuticals are not toxic for the environment, do not bioaccumulate and degrade into harmless substances, particularly in wastewater treatment plants and the environment;
Amendment 692 #
Motion for a resolution
Paragraph 22 – point a (new)
Paragraph 22 – point a (new)
Amendment 697 #
Motion for a resolution
Paragraph 22 – point d (new)
Paragraph 22 – point d (new)
(d) Calls on the Commission to include pharmaceuticals that pose a risk to the environment in the list of priority substances under the Water Framework Directive and to set strict environmental quality standards and concentration limits under the Environmental Quality Standards (EOS) Directive;
Amendment 699 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22a. Calls on the Commission to examine the contribution of the pharmaceutical sector to climate change through greenhouse gas emissions; calls for special attention to be paid to emission hot spots, such as hospitals, pharmaceutical plants and intensive stockbreeding areas;